Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

Lignende værker

• Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
  af: Norris, Stephen, et al.
  Udgivet: (2017)
• Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
  af: Glund, Stephan, et al.
  Udgivet: (2019)
• Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
  af: Glund, Stephan, et al.
  Udgivet: (2016)
• The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
  af: Stangier, Joachim, et al.
  Udgivet: (2007)
• Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
  af: Glund, Stephan, et al.
  Udgivet: (2016)